TLRY Stock Risk & Deep Value Analysis
Tilray Brands Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
The Bottom Line on TLRY
We analyzed Tilray Brands Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TLRY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
TLRY Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Tilray Brands Inc (TLRY)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market Cap Category
small
Market Cap
$1.11B
TLRY Deep Value Analysis
Compare TLRY to Similar Stocks
See how Tilray Brands Inc stacks up against related companies in our head-to-head analysis.
TLRY Red Flags & Warning Signs
- âš
Delays or negative changes in German or other international cannabis regulatory timelines
- âš
Continued shareholder dilution without corresponding growth in shareholder value
- âš
Worse-than-expected earnings reports or guidance
- âš
Increased competition eroding market share in key segments
Unlock TLRY Red Flags & Risk Warnings
Create a free account to see the full analysis
TLRY Financial Health Metrics
Market Cap
$1.11B
TLRY Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Stable
Moat Sources
3 Identified
The moat is primarily derived from its established CPG brands and early-mover advantage in certain international cannabis markets. This provides some brand loyalty and distribution scale. However, the cannabis segment of the moat is susceptible to regulatory changes and intense competition, making it less durable than the CPG component. Its persistence relies on effective execution and market capture ahead of competitors.
TLRY Competitive Moat Analysis
Sign up to see competitive advantages
TLRY Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q3 FY2026 Earnings Report (estimated April 2026)
- •Finalization of German cannabis legalization framework and commercial implementation
- •New product launches in existing CPG or cannabis markets
Medium-Term (6-18 months)
- •Expansion into other European cannabis markets (e.g., Poland, UK medical)
- •Accelerated growth of CPG brands (SweetWater, Breckenridge) in new geographies or channels
- •Intensification of US federal cannabis reform discussions or significant legislative progress
Long-Term (18+ months)
- •Full US federal legalization, enabling direct market entry and consolidation
- •Tilray establishing global cannabis market leadership with diversified revenue streams
- •Potential for M&A activity within the consolidating cannabis sector
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
TLRY Bull Case: What Could Go Right
- ✓
Accelerated revenue growth rates in international cannabis and CPG segments
- ✓
Consistent positive free cash flow generation and significant debt reduction
- ✓
Concrete legislative progress towards US federal cannabis legalization
- ✓
Decreased shareholder dilution via equity offerings
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
